{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:59:01Z","timestamp":1790690341241,"version":"4.1.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Diffuse large B-cell lymphoma (DLBCL) encompasses a group of aggressive B-cell non-Hodgkin lymphomas with striking genetic heterogeneity and variable clinical presentations. Among these is primary mediastinal B-cell lymphoma (PMBL), which has unique clinical and molecular features resembling Hodgkin lymphoma. Treatment of DLBCL is usually curative, but identifiable subsets at highest risk for treatment failure may benefit from intensified chemotherapy regimens and\/or targeted agents added to frontline therapy. Recent comprehensive genomic analyses have identified distinct genetic subtypes of DLBCL with characteristic genetic drivers and signaling pathways that are targetable. Immune therapy with chimeric antigen receptor T cells and checkpoint inhibitors has revolutionized the treatment of relapsed or refractory disease, and antibody drug conjugates have weaponized otherwise intolerable cytotoxic agents. Ongoing clinical trials are further refining the specificity of these approaches in different genetic subtypes and moving them from the setting of recurrent disease to frontline treatment in high-risk patient populations.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000450","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T21:02:18Z","timestamp":1591909338000},"page":"195-205","source":"Crossref","is-referenced-by-count":52,"title":["Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma"],"prefix":"10.1097","volume":"26","author":[{"given":"Mark","family":"Roschewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","year":"2000","journal-title":"Nature"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib8-20230924","first-page":"2271","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","year":"2020","journal-title":"Lancet"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","article-title":"Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for Bias in clinical trials","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-cancerbio-030518-055734","article-title":"Taming the heterogeneity of aggressive lymphomas for precision therapy","volume":"3","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell\u2013like diffuse large B cell lymphoma cells","volume":"194","year":"2001","journal-title":"J Exp Med"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","year":"2010","journal-title":"Nature"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","year":"2003","journal-title":"J Exp Med"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","year":"2003","journal-title":"Blood"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2011-05-326538","article-title":"The molecular pathogenesis of primary mediastinal large B-cell lymphoma","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","year":"2011","journal-title":"Nat Genet"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","year":"2011","journal-title":"Nature"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","year":"2015","journal-title":"Semin Hematol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","year":"2017","journal-title":"Cancer Cell"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) network","volume":"117","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","year":"2018","journal-title":"Nat Med"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","year":"2011","journal-title":"Nature"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00705408","article-title":"Primary mediastinal clear cell lymphoma of B-cell type","volume":"409","year":"1986","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"bib39-20230924","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","article-title":"Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2004-12-4901","article-title":"NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes","volume":"106","year":"2005","journal-title":"Blood"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood-2003-10-3545","article-title":"Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma","volume":"104","year":"2004","journal-title":"Blood"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood.V87.4.1571.bloodjournal8741571","article-title":"Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene","volume":"87","year":"1996","journal-title":"Blood"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","year":"2009","journal-title":"J Exp Med"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood-2016-03-704528","article-title":"Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","article-title":"Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","year":"2014","journal-title":"Nat Genet"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","article-title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib48-20230924","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","year":"2010","journal-title":"Blood"},{"key":"bib49-20230924","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","year":"2010","journal-title":"Cancer Cell"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib51-20230924","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","year":"2011","journal-title":"Nature"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.celrep.2015.10.008","article-title":"Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression","volume":"13","year":"2015","journal-title":"Cell Rep"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","year":"2010","journal-title":"Nat Genet"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"bib59-20230924","first-page":"248","article-title":"Advanced diffuse histiocytic lymphoma, a potentially curable disease","volume":"1","year":"1975","journal-title":"Lancet"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group","volume":"7","year":"2006","journal-title":"Lancet Oncol"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","year":"2011","journal-title":"Lancet"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"bib66-20230924","first-page":"758","article-title":"A Cancer and Leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","year":"2011","journal-title":"Haematologica"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib69-20230924","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nri3190","article-title":"Integration of B cell responses through Toll-like receptors and antigen receptors","volume":"12","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","year":"2009","journal-title":"Nature"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/13543784.2012.656199","article-title":"PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies","volume":"21","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","year":"2015","journal-title":"Nat Med"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","year":"2018","journal-title":"Nature"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell\u2013like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","year":"2013","journal-title":"Br J Haematol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell\u2013like than in germinal center B-cell\u2013like phenotype","volume":"117","year":"2011","journal-title":"Cancer"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2019-128475","article-title":"Smart start: rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma: final phase II results","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell\u2013like diffuse large B-cell lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","year":"2018","journal-title":"Lancet Haematol"},{"key":"bib84-20230924","first-page":"1258","article-title":"Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients","volume":"87","year":"2002","journal-title":"Haematologica"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.14287","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial","volume":"175","year":"2016","journal-title":"Br J Haematol"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making","volume":"103","year":"2018","journal-title":"Haematologica"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis","volume":"180","year":"2018","journal-title":"Br J Haematol"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib94-20230924","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","year":"2012","journal-title":"Cancer Cell"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2019-121521","article-title":"Phase 2 results of the iR2 regimen (ibrutinib, lenalidomide, and rituximab) in patients with relapsed\/refractory (R\/R) non-germinal center B cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL)","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib101-20230924","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell\u2013like diffuse large B-cell lymphoma cells","volume":"111","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib103-20230924","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2019-125990","article-title":"Phase 1b study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed\/refractory B-cell lymphoma: safety, efficacy and molecular analysis","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib105-20230924","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3Kalpha\/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:26:55Z","timestamp":1695533215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000450","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}